Hoppa till innehåll

Two years risdiplam: New data from SUNFISH, JEWELFISH in infants, children, adults with spinal muscular atrophy (SMA)

Roche announces new 2-year risdiplam data to

SUNFISH Part 1 showed risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with Types 2 or 3 SMA
JEWELFISH study preliminary 12 month data in previously treated patients showed rapid and sustained increases in SMN protein levels
Safety in SUNFISH and JEWELFISH was consistent with the safety profile observed to date and no new safety signals were identified

Read more

Only for Members
Roche bringing patient support for spinal muscular atrophy (SMA) with Risdiplam

Publicerat iSMA